Takeda gets European Commission approval for Fruzaqla for previously treated metastatic Colorectal cancer
Osaka: Takeda has announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard …